Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BIVV020

Phase 2Small molecule

BIVV020 is one of 7 small molecule programs targeting Transplant. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

6

Competitors

Pipeline

Status by Indication[3][1]

Indication

TransplantActive, not recruiting

TransplantPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Transplant

#DrugCompanyPhaseTrials

Rituxan

Myfortic

Prograf

VVeloxis Pharmaceuticals

Immunoglobulin

Antithymocyte Globulin

Intravenous Immunoglobulin

UUniversity of Alabama at Birmingham

BIVV020

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Transplant

NCT05156710

Clinical

Trials by Indication[1]

Cold Agglutinin Disease1 trial

A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease

Completed·BBioverativ, a Sanofi company·Phase 1·NCT04269551·12 enrolled

Transplant1 trial

A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT05156710·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BIVV020. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIVV020 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIVV020. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Related News